The potential regulatory role of RNA methylation in ovarian cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.
   PubMed Web of Science ®Google Scholar
• Cao W, Chen H-D, Yu Y-W, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134:783–791.
   PubMed Web of Science ®Google Scholar
• Bitler BG, Watson ZL, Wheeler LJ, et al. PARP inhibitors: clinical utility and possibilities of overcoming resistance. Gynecol Oncol. 2017;147:695–704.
   PubMed Web of Science ®Google Scholar
• Morand S, Devanaboyina M, Staats H, et al. Ovarian cancer immunotherapy and personalized medicine. Int J Mol Sci. 2021;22:6532.
   PubMed Web of Science ®Google Scholar
• He L, Li H, Wu A, et al. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18:176.
   PubMed Web of Science ®Google Scholar
• Xue C, Zhao Y, Li L. Advances in RNA cytosine-5 methylation: detection, regulatory mechanisms, biological functions and links to cancer. Biomark Res. 2020;8:43.
   PubMed Web of Science ®Google Scholar
• Nombela P, Miguel-López B, Blanco S. The role of m6A, m5C and Ψ RNA modifications in cancer: novel therapeutic opportunities. Mol Cancer. 2021;20:18.
   PubMed Web of Science ®Google Scholar
• Zhao L-Y, Song J, Liu Y, et al. Mapping the epigenetic modifications of DNA and RNA. Protein Cell. 2020;11:792–808.
   PubMed Web of Science ®Google Scholar
• Xiang Y, Laurent B, Hsu C-H, et al. RNA m6A methylation regulates the ultraviolet-induced DNA damage response. Nature. 2017;543:573–576.
   PubMed Web of Science ®Google Scholar
• Frye M, Harada BT, Behm M, et al. RNA modifications modulate gene expression during development. Science. 2018;361:1346–1349.
   PubMed Web of Science ®Google Scholar
• Li X, Xiong X, Yi C. Epitranscriptome sequencing technologies: decoding RNA modifications. Nat Methods. 2016;14:23–31.
   PubMed Web of Science ®Google Scholar
• Li X, Liang Q-X, Lin J-R, et al. Epitranscriptomic technologies and analyses. Sci China Life Sci. 2020;63:501–515.
   PubMed Web of Science ®Google Scholar
• Barbieri I, Kouzarides T. Role of RNA modifications in cancer. Nat Rev Cancer. 2020;20:303–322.
   PubMed Web of Science ®Google Scholar
• Sun T, Wu R, Ming L. The role of m6A RNA methylation in cancer. Biomed Pharmacother. 2019;112:108613.
   PubMed Web of Science ®Google Scholar
• Xu Q-C, Tien Y-C, Shi Y-H, et al. METTL3 promotes intrahepatic cholangiocarcinoma progression by regulating IFIT2 expression in an m6A-YTHDF2-dependent manner. Oncogene. 2022;41:1622–1633.
   PubMed Web of Science ®Google Scholar
• Yang X, Yang Y, Sun B-F, et al. 5-methylcytosine promotes mRNA export - NSUN2 as the methyltransferase and ALYREF as an m5C reader. Cell Res. 2017;27:606–625.
   PubMed Web of Science ®Google Scholar
• He Y, Yu X, Li J, et al. Role of m5C-related regulatory genes in the diagnosis and prognosis of hepatocellular carcinoma. Am J Transl Res. 2020;12:912–922.
   PubMed Web of Science ®Google Scholar
• L X, M Y. Expression and prognostic characteristics of m5 C regulators in low-grade glioma. J Cell Mol Med. 2021;25:1383–1393.
   PubMed Web of Science ®Google Scholar
• Esteve-Puig R, Climent F, Piñeyro D, et al. Epigenetic loss of m1A RNA demethylase ALKBH3 in Hodgkin lymphoma targets collagen, conferring poor clinical outcome. Blood. 2021;137:994–999.
   PubMed Web of Science ®Google Scholar
• Ying X, Liu B, Yuan Z, et al. METTL1-m7 G-EGFR/EFEMP1 axis promotes the bladder cancer development. Clin Transl Med. 2021;11:e675.
   PubMed Web of Science ®Google Scholar
• Bokar JA, Shambaugh ME, Polayes D, et al. Purification and cDNA cloning of the AdoMet-binding subunit of the human mRNA (N6-adenosine)-methyltransferase. RNA. 1997;3:1233–1247.
   PubMed Web of Science ®Google Scholar
• Bi X, Lv X, Liu D, et al. METTL3-mediated maturation of miR-126-5p promotes ovarian cancer progression via PTEN-mediated PI3K/Akt/mTOR pathway. Cancer Gene Ther. 2021;28:335–349.
   PubMed Web of Science ®Google Scholar
• Ma Z, Li Q, Liu P, et al. METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP. Cell Biol Int. 2020;44:2524–2531.
   PubMed Web of Science ®Google Scholar
• Schwartz S, Mumbach MR, Jovanovic M, et al. Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5’ sites. Cell Rep. 2014;8:284–296.
   PubMed Web of Science ®Google Scholar
• Li Y, Peng H, Jiang P, et al. Downregulation of methyltransferase-like 14 promotes ovarian cancer cell proliferation through stabilizing TROAP mRNA. Front Oncol. 2022;12:824258.
   PubMed Web of Science ®Google Scholar
• Su R, Dong L, Li Y, et al. METTL16 exerts an m6A-independent function to facilitate translation and tumorigenesis. Nat Cell Biol. 2022;24:205–216.
   PubMed Web of Science ®Google Scholar
• Agarwala SD, Blitzblau HG, Hochwagen A, et al. RNA methylation by the MIS complex regulates a cell fate decision in yeast. PLoS Genet. 2012;8:e1002732.
   PubMed Web of Science ®Google Scholar
• Yu H-L, Ma X-D, Tong J-F, et al. WTAP is a prognostic marker of high-grade serous ovarian cancer and regulates the progression of ovarian cancer cells. Onco Targets Ther. 2019;12:6191–6201.
   PubMed Web of Science ®Google Scholar
• Zhang C, Liu J, Guo H, et al. M6a RNA methylation regulators were associated with the malignancy and prognosis of ovarian cancer. Bioengineered. 2021;12:3159–3176.
   PubMed Web of Science ®Google Scholar
• M(6)a RNA methylation promotes XIST-mediated transcriptional repression - PubMed. [update 2022 Nov 1]. Available from: https://pubmed.ncbi.nlm.nih.gov/27602518/
   Google Scholar
• Wang Q, Zhang Q, Li Q, et al. Clinicopathological and immunological characterization of RNA m6 a methylation regulators in ovarian cancer. Mol Genet Genomic Med. 2021;9:e1547.
   PubMed Web of Science ®Google Scholar
• Wen J, Lv R, Ma H, et al. Zc3h13 regulates nuclear RNA m6A methylation and mouse embryonic stem cell self-renewal. Mol Cell. 2018;69:1028–1038.e6.
   PubMed Web of Science ®Google Scholar
• Tan W, Liu S, Deng Z, et al. Gene signature of m6A-related targets to predict prognosis and immunotherapy response in ovarian cancer. J Cancer Res Clin Oncol. 2022; DOI:10.1007/s00432-022-04162-3
   Web of Science ®Google Scholar
• J G, F Y, Z X, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011;7:885–887.
   PubMed Web of Science ®Google Scholar
• Zheng G, Dahl JA, Niu Y, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell. 2013;49:18–29.
   PubMed Web of Science ®Google Scholar
• Cai Y, Wu G, Peng B, et al. Expression and molecular profiles of the AlkB family in ovarian serous carcinoma. Aging. 2021;13:9679–9692.
   PubMedGoogle Scholar
• Wang X, Zhao BS, Roundtree IA, et al. N(6)-methyladenosine modulates messenger RNA translation efficiency. Cell. 2015;161:1388–1399.
   PubMed Web of Science ®Google Scholar
• Shi H, Wang X, Lu Z, et al. YTHDF3 facilitates translation and decay of N6-methyladenosine-modified RNA. Cell Res. 2017;27:315–328.
   PubMed Web of Science ®Google Scholar
• Liu T, Wei Q, Jin J, et al. The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Nucleic Acids Res. 2020;48:3816–3831.
   PubMed Web of Science ®Google Scholar
• Xu F, Li J, Ni M, et al. FBW7 suppresses ovarian cancer development by targeting the N6-methyladenosine binding protein YTHDF2. Mol Cancer. 2021;20:45.
   PubMed Web of Science ®Google Scholar
• Xiao W, Adhikari S, Dahal U, et al. Nuclear m(6)A reader YTHDC1 regulates mRNA splicing. Mol Cell. 2016;61:507–519.
   PubMed Web of Science ®Google Scholar
• Hsu PJ, Zhu Y, Ma H, et al. Ythdc2 is an N6-methyladenosine binding protein that regulates mammalian spermatogenesis. Cell Res. 2017;27:1115–1127.
   PubMed Web of Science ®Google Scholar
• Huang H, Weng H, Sun W, et al. Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20:285–295.
   PubMed Web of Science ®Google Scholar
• Müller S, Bley N, Glaß M, et al. IGF2BP1 enhances an aggressive tumor cell phenotype by impairing miRNA-directed downregulation of oncogenic factors. Nucleic Acids Res. 2018;46:6285–6303.
   PubMed Web of Science ®Google Scholar
• Zhou KI, Shi H, Lyu R, et al. Regulation of co-transcriptional pre-mRNA splicing by m6A through the low-complexity protein hnRNPG. Mol Cell. 2019;76:70–81.e9.
   PubMed Web of Science ®Google Scholar
• Liu N, Dai Q, Zheng G, et al. N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature. 2015;518:560–564.
   PubMed Web of Science ®Google Scholar
• Wu B, Su S, Patil DP, et al. Molecular basis for the specific and multivariant recognitions of RNA substrates by human hnRNP A2/B1. Nat Commun. 2018;9:420.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wei Q, Tang Y, et al. Loss of hnRNPA2B1 inhibits malignant capability and promotes apoptosis via down-regulating Lin28B expression in ovarian cancer. Cancer Lett. 2020;475:43–52.
   PubMed Web of Science ®Google Scholar
• Motorin Y, Lyko F, Helm M. 5-methylcytosine in RNA: detection, enzymatic formation and biological functions. Nucleic Acids Res. 2010;38:1415–1430.
   PubMed Web of Science ®Google Scholar
• Popis MC, Blanco S, Frye M. Posttranscriptional methylation of transfer and ribosomal RNA in stress response pathways, cell differentiation, and cancer. Curr Opin Oncol. 2016;28:65–71.
   PubMed Web of Science ®Google Scholar
• Teng Y, Zuo X, Hou M, et al. A double-negative feedback interaction between MicroRNA-29b and DNMT3A/3B contributes to ovarian cancer progression. Cell Physiol Biochem. 2016;39:2341–2352.
   PubMedGoogle Scholar
• Basaki Y, Hosoi F, Oda Y, et al. Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells. Oncogene. 2007;26:2736–2746.
   PubMed Web of Science ®Google Scholar
• Xu J, Liu X, Chen Y, et al. RNA 5-methylcytosine regulators contribute to metabolism heterogeneity and predict prognosis in ovarian cancer. Front Cell Dev Biol. 2022;10:807786.
   PubMed Web of Science ®Google Scholar
• Dominissini D, Nachtergaele S, Moshitch-Moshkovitz S, et al. The dynamic N(1)-methyladenosine methylome in eukaryotic messenger RNA. Nature. 2016;530:441–446.
   PubMed Web of Science ®Google Scholar
• Zhou H, Rauch S, Dai Q, et al. Evolution of a reverse transcriptase to map N1-methyladenosine in human messenger RNA. Nat Methods. 2019;16:1281–1288.
   PubMed Web of Science ®Google Scholar
• Chen Z, Qi M, Shen B, et al. Transfer RNA demethylase ALKBH3 promotes cancer progression via induction of tRNA-derived small RNAs. Nucleic Acids Res. 2019;47:2533–2545.
   PubMed Web of Science ®Google Scholar
• Liu F, Clark W, Luo G, et al. ALKBH1-mediated tRNA demethylation regulates translation. Cell. 2016;167:816–828.e16.
   PubMed Web of Science ®Google Scholar
• Woo H-H, Chambers SK. Human ALKBH3-induced m1A demethylation increases the CSF-1 mRNA stability in breast and ovarian cancer cells. Biochim Biophys Acta, Gene Regul Mech. 2019;1862:35–46.
   PubMed Web of Science ®Google Scholar
• Seo KW, Kleiner RE. YTHDF2 recognition of N1-methyladenosine (m1A)-modified RNA is associated with transcript destabilization. ACS Chem Biol. 2020;15:132–139.
   PubMed Web of Science ®Google Scholar
• Furuichi Y. Discovery of m(7)G-cap in eukaryotic mRnas. Proc Jpn Acad Ser B Phys Biol Sci. 2015;91:394–409.
   PubMed Web of Science ®Google Scholar
• Furuichi Y, LaFiandra A, Shatkin AJ. 5’-Terminal structure and mRNA stability. Nature. 1977;266:235–239.
   PubMed Web of Science ®Google Scholar
• Shimotohno K, Kodama Y, Hashimoto J, et al. Importance of 5’-terminal blocking structure to stabilize mRNA in eukaryotic protein synthesis. Proc Natl Acad Sci U S A. 1977;74:2734–2738.
   PubMed Web of Science ®Google Scholar
• Alexandrov A, Martzen MR, Phizicky EM. Two proteins that form a complex are required for 7-methylguanosine modification of yeast tRNA. RNA. 2002;8:1253–1266.
   PubMed Web of Science ®Google Scholar
• Trotman JB, Giltmier AJ, Mukherjee C, et al. RNA guanine-7 methyltransferase catalyzes the methylation of cytoplasmically recapped RNAs. Nucleic Acids Res. 2017;45:10726–10739.
   PubMed Web of Science ®Google Scholar
• Luo Y, Yao Y, Wu P, et al. The potential role of N7-methylguanosine (m7G) in cancer. J Hematol Oncol. 2022;15:63.
   PubMed Web of Science ®Google Scholar
• Liu K, Gao Y, Gan K, et al. Prognostic roles of N6-methyladenosine METTL3 in different cancers: a system review and meta-analysis. Cancer Control. 2021;28:1073274821997455.
   Web of Science ®Google Scholar
• Han X, Liu J, Cheng G, et al. Gene signatures and prognostic values of m6A RNA methylation regulators in ovarian cancer. Cancer Control. 2020;27:1073274820960460.
   Web of Science ®Google Scholar
• Wei Q, Yang D, Liu X, et al. Exploration of the role of m6 a RNA methylation regulators in malignant progression and clinical prognosis of ovarian cancer. Front Genet. 2021;12:650554.
   PubMed Web of Science ®Google Scholar
• Fan L, Lin Y, Lei H, et al. A newly defined risk signature, consisting of three m6A RNA methylation regulators, predicts the prognosis of ovarian cancer. Aging. 2020;12:18453–18475.
   PubMedGoogle Scholar
• Wei YS, Yao DS, Li L, et al. Expression of METTL14 in epithelial ovarian cancer and the effect on cell proliferation, invasion and migration of A2780 and SKOV3 cells. Zhonghua Fu Chan Ke Za Zhi. 2022;57:46–56.
   PubMedGoogle Scholar
• Li Q, Ren C-C, Chen Y-N, et al. A risk score model incorporating three m6A RNA methylation regulators and a related network of miRnas-m6A regulators-m6A Target genes to predict the prognosis of patients with ovarian cancer. Front Cell Dev Biol. 2021;9:703969.
   PubMed Web of Science ®Google Scholar
• Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10:155–159.
   PubMed Web of Science ®Google Scholar
• Song Y, Qu H. Identification and validation of a seven m6A-related lncRnas signature predicting prognosis of ovarian cancer. BMC Cancer. 2022;22:633.
   PubMed Web of Science ®Google Scholar
• Ni X, Chen C, Cui G, et al. Crosstalk of RNA adenosine modification-related subtypes, establishment of a prognostic model, and immune infiltration characteristics in ovarian cancer. Front Immunol. 2022;13:932876.
   PubMed Web of Science ®Google Scholar
• Zhang L-Y, Li P-L, Wang T-Z, et al. Prognostic values of 5-hmC, 5-Mc and TET2 in epithelial ovarian cancer. Arch Gynecol Obstet. 2015;292:891–897.
   PubMed Web of Science ®Google Scholar
• Wang L, Gao S. Identification of 5-methylcytosine-related signature for predicting prognosis in ovarian cancer. Biol Res. 2021;54:18.
   PubMed Web of Science ®Google Scholar
• Oda Y, Ohishi Y, Basaki Y, et al. Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/MVP and P-glycoprotein expression. Cancer Sci. 2007;98:1020–1026.
   PubMed Web of Science ®Google Scholar
• M L, Z Q, H X. Abnormal 5-methylcytosine lncRNA methylome is involved in human high-grade serous ovarian cancer. Am J Transl Res. 2021;13:13625–13639.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang Q, Huang Y, et al. M1a regulator TRMT10C predicts poorer survival and contributes to malignant behavior in gynecological cancers. DNA Cell Biol. 2020;39:1767–1778.
   PubMed Web of Science ®Google Scholar
• Liu J, Chen C, Wang Y, et al. Comprehensive of N1-methyladenosine modifications patterns and immunological characteristics in ovarian cancer. Front Immunol. 2021;12:746647.
   PubMed Web of Science ®Google Scholar
• Li L, Yang Y, Wang Z, et al. Prognostic role of METTL1 in glioma. Cancer Cell Int. 2021;21:633.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Wan Y, Gong M, et al. RNA demethylase ALKBH5 promotes ovarian carcinogenesis in a simulated tumour microenvironment through stimulating NF-κB pathway. J Cell Mol Med. 2020;24:6137–6148.
   PubMed Web of Science ®Google Scholar
• Meng L, Zhang Q, Huang X. Comprehensive analysis of 5-methylcytosine profiles of messenger RNA in human high-grade serous ovarian cancer by MeRIP sequencing. Cancer Manag Res. 2021;13:6005–6018.
   PubMed Web of Science ®Google Scholar
• Cui S. METTL3-mediated m6A modification of lnc RNA RHPN1-AS1 enhances cisplatin resistance in ovarian cancer by activating PI3K/AKT pathway. J Clin Lab Anal. 2022;36:e24761.
   PubMed Web of Science ®Google Scholar
• Liang S, Guan H, Lin X, et al. METTL3 serves an oncogenic role in human ovarian cancer cells partially via the AKT signaling pathway. Oncol Lett. 2020;19:3197–3204.
   PubMed Web of Science ®Google Scholar
• Lyu Y, Zhang Y, Wang Y, et al. HIF-1α regulated WTAP overexpression promoting the Warburg effect of ovarian cancer by m6A-Dependent manner. J Immunol Res. 2022;2022:6130806.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen Z. Long noncoding RNA UBA6-AS1 inhibits the malignancy of ovarian cancer cells via suppressing the decay of UBA6 mRNA. Bioengineered. 2022;13:178–189.
   PubMed Web of Science ®Google Scholar
• Zhu H, Gan X, Jiang X, et al. ALKBH5 inhibited autophagy of epithelial ovarian cancer through miR-7 and BCL-2. J Exp Clin Cancer Res. 2019;38:163.
   PubMed Web of Science ®Google Scholar
• Li J, Wu L, Pei M, et al. YTHDF2, a protein repressed by miR-145, regulates proliferation, apoptosis, and migration in ovarian cancer cells. J Ovarian Res. 2020;13:111.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang J, Su Y, et al. Distinct roles of m5C RNA methyltransferase NSUN2 in major gynecologic cancers. Front Oncol. 2022;12:786266.
   PubMed Web of Science ®Google Scholar
• Gu J, Bi F. Significance of N6-methyladenosine RNA methylation regulators in immune infiltrates of ovarian cancer. Front Genet. 2021;12:671179.
   PubMed Web of Science ®Google Scholar
• Shen Z, Gu L, Liu Y, et al. PLAA suppresses ovarian cancer metastasis via METTL3-mediated m6A modification of TRPC3 mRNA. Oncogene. 2022;41:4145–4158.
   PubMed Web of Science ®Google Scholar
• Huang H, Wang Y, Kandpal M, et al. FTO-Dependent N 6-methyladenosine modifications inhibit ovarian cancer stem cell self-renewal by blocking cAMP signaling. Cancer Res. 2020;80:3200–3214.
   PubMed Web of Science ®Google Scholar
• Hao L, Wang J-M, Liu B-Q, et al. M6A-YTHDF1-mediated TRIM29 upregulation facilitates the stem cell-like phenotype of cisplatin-resistant ovarian cancer cells. Biochim Biophys Acta, Mol Cell Res. 2021;1868:118878.
   PubMed Web of Science ®Google Scholar
• Chen B, Ye F, Yu L, et al. Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor. J Am Chem Soc. 2012;134:17963–17971.
   PubMed Web of Science ®Google Scholar
• Huang Y, Yan J, Li Q, et al. Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5. Nucleic Acids Res. 2015;43:373–384.
   PubMed Web of Science ®Google Scholar
• Huang Y, Su R, Sheng Y, et al. Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia. Cancer Cell. 2019;35:677–691.e10.
   PubMed Web of Science ®Google Scholar
• Xie G, Wu X-N, Ling Y, et al. A novel inhibitor of N 6-methyladenosine demethylase FTO induces mRNA methylation and shows anti-cancer activities. Acta Pharm Sin B. 2022;12:853–866.
   PubMed Web of Science ®Google Scholar
• Sugihara H, Miyaji K, Yamanouchi K, et al. Progranulin deficiency leads to prolonged persistence of macrophages, accompanied with myofiber hypertrophy in regenerating muscle. J Vet Med Sci. 2018;80:346–353.
   PubMed Web of Science ®Google Scholar
• Zheng G, Cox T, Tribbey L, et al. Synthesis of a FTO inhibitor with anticonvulsant activity. ACS Chem Neurosci. 2014;5:658–665.
   PubMed Web of Science ®Google Scholar
• Chen J, Wei X, Wang X, et al. TBK1-METTL3 axis facilitates antiviral immunity. Cell Rep. 2022;38:110373.
   PubMed Web of Science ®Google Scholar
• Lee J-H, Choi N, Kim S, et al. Eltrombopag as an allosteric inhibitor of the METTL3-14 complex affecting the m6A methylation of RNA in acute myeloid leukemia cells. Pharmaceuticals (Basel). 2022;15:440.
   PubMedGoogle Scholar
• Li N, Kang Y, Wang L, et al. ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. Proc Natl Acad Sci U S A. 2020;117:20159–20170.
   PubMed Web of Science ®Google Scholar
• Wallis N, Oberman F, Shurrush K, et al. Small molecule inhibitor of Igf2bp1 represses Kras and a pro-oncogenic phenotype in cancer cells. RNA Biol. 2022;19:26–43.
   PubMed Web of Science ®Google Scholar
• Nie S, Zhang L, Liu J, et al. ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer. J Exp Clin Cancer Res. 2021;40:284.
   PubMed Web of Science ®Google Scholar
• Fukumoto T, Zhu H, Nacarelli T, et al. N6-methylation of adenosine of FZD10 mRNA contributes to PARP inhibitor resistance. Cancer Res. 2019;79:2812–2820.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Qiu J-G, Jia X-Y, et al. METTL3-mediated N6-methyladenosine modification and HDAC5/YY1 promote IFFO1 downregulation in tumor development and chemo-resistance. Cancer Lett. 2023;553:215971.
   PubMed Web of Science ®Google Scholar
• Gao W, Chen L, Lin L, et al. SIAH1 reverses chemoresistance in epithelial ovarian cancer via ubiquitination of YBX-1. Oncogenesis. 2022;11:13.
   PubMed Web of Science ®Google Scholar
• Xiang Y, Ma N, Wang D, et al. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene. 2014;33:378–386.
   PubMed Web of Science ®Google Scholar
• Han X, Liu D, Zhou Y, et al. The negative feedback between miR-143 and DNMT3A regulates cisplatin resistance in ovarian cancer. Cell Biol Int. 2021;45:227–237.
   PubMed Web of Science ®Google Scholar
• Chen B, Jiang W, Huang Y, et al. N7-methylguanosine tRNA modification promotes tumorigenesis and chemoresistance through WNT/β-catenin pathway in nasopharyngeal carcinoma. Oncogene. 2022;41:2239–2253.
   PubMed Web of Science ®Google Scholar
• Okamoto M, Fujiwara M, Hori M, et al. tRNA modifying enzymes, NSUN2 and METTL1, determine sensitivity to 5-fluorouracil in HeLa cells. PLoS Genet. 2014;10:e1004639.
   PubMed Web of Science ®Google Scholar
• Xia P, Zhang H, Xu K, et al. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma. Cell Death Dis. 2021;12:691.
   PubMed Web of Science ®Google Scholar
• Denis H, Ndlovu MN, Fuks F. Regulation of mammalian DNA methyltransferases: a route to new mechanisms. EMBO Rep. 2011;12:647–656.
   PubMed Web of Science ®Google Scholar
• Issa JP, Baylin SB, Herman JG. DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia. 1997;11(Suppl 1):S7–11.
   PubMed Web of Science ®Google Scholar
• Candelaria M, Gallardo-Rincón D, Arce C, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol. 2007;18:1529–1538.
   PubMed Web of Science ®Google Scholar
• Newman EM, Morgan RJ, Kummar S, et al. A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2’-deoxycytidine, administered with tetrahydrouridine. Cancer Chemother Pharmacol. 2015;75:537–546.
   PubMed Web of Science ®Google Scholar
• Dimitrova E, Turberfield AH, Klose RJ. Histone demethylases in chromatin biology and beyond. EMBO Rep. 2015;16:1620–1639.
   PubMed Web of Science ®Google Scholar
• Klose RJ, Kallin EM, Zhang Y. JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet. 2006;7:715–727.
   PubMed Web of Science ®Google Scholar
• Schmidt DMZ, McCafferty DG. Trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Biochemistry. 2007;46:4408–4416.
   PubMed Web of Science ®Google Scholar
• Mohammad HP, Smitheman KN, Kamat CD, et al. A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC. Cancer Cell. 2015;28:57–69.
   PubMed Web of Science ®Google Scholar
• Huang Y, Stewart TM, Wu Y, et al. Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin Cancer Res. 2009;15:7217–7228.
   PubMed Web of Science ®Google Scholar
• Murray-Stewart T, Woster PM, Casero RA. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines. Amino Acids. 2014;46:585–594.
   PubMed Web of Science ®Google Scholar
• Zhu Q, Huang Y, Marton LJ, et al. Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells. Amino Acids. 2012;42:887–898.
   PubMed Web of Science ®Google Scholar
• Zhang J, Bai R, Li M, et al. Excessive miR-25-3p maturation via N6-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Nat Commun. 2019;10:1858.
   PubMed Web of Science ®Google Scholar
• Li Y, Xia L, Tan K, et al. N6-methyladenosine co-transcriptionally directs the demethylation of histone H3K9me2. Nat Genet. 2020;52:870–877.
   PubMed Web of Science ®Google Scholar
• Huang H, Weng H, Zhou K, et al. Histone H3 trimethylation at lysine 36 guides m6A RNA modification co-transcriptionally. Nature. 2019;567:414–419.
   PubMed Web of Science ®Google Scholar